OncoMatch/Clinical Trials/NCT06883526
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Is NCT06883526 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including ZG005 for and Gecacitinib Hydrochloride Tablets for lymphoma.
Treatment: ZG005 for · Gecacitinib Hydrochloride Tablets — PART 1: 1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma. 2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma. PART 2: To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06883526 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages